Skip to content

A Dyadic Approach to Cancer Care: a Feasibility and Efficacy Partner-based Exercise Study

A Dyadic Approach to Cancer Care: a Feasibility and Efficacy Partner-based Exercise Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05333016
Acronym
C4C
Enrollment
42
Registered
2022-04-18
Start date
2023-01-15
Completion date
2024-12-31
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, Caregiver burden, Survivor, Dyad, Exercise, Intervention, Feasibility

Brief summary

The primary goal of this study will be to assess the feasibility and acceptability of a partner-based 12-week exercise intervention for cancer caregivers and their care recipient. The researchers will also explore the preliminary effectiveness of the exercise program on caregiver burden and physical and psychological health of both the family caregiver and the care recipient.

Detailed description

NEED: Cancer has been characterized as a family affair, as it is a disease in which both the patient and their family members are confronted by considerable physical and psychological stressors. With an anticipated 80% increase in the average number of new cancer diagnoses by 2030 and rapidly escalating health care costs, there has been a shift to outpatient and home-based care. In doing so, family members are increasingly being called upon to participate as informal caregivers (i.e., an individual who provided uncompensated care). Despite being a key partner in the supportive care of the cancer patient, family caregivers are often inadequately prepared or supported to take on this critical role, subsequently putting their own health and well-being at risk and by extension, that of the cancer patient/survivor. Preliminary data suggests that exercise interventions show promise in mitigating caregiver burden and improving health outcomes for both the caregiver and the patient/survivor. To date, however only two studies have examined the benefit of exercise interventions on family caregiver and patient outcomes within the cancer care context. GOAL: The primary goal of this study will be to assess the feasibility and acceptability of a partner-based 12-week exercise intervention. The investigators will also explore the preliminary effectiveness of the exercise program on caregiver burden and physical and psychological health of both the family caregiver and the care recipient. WHO: Participants will include adult primary caregivers and cancer patients/survivors of all cancers and stages at any point along the cancer care trajectory. HOW: Using both surveys and participant interviews, the participant experience and impact (e.g., physical and psychological health benefits) of a 12-week, partner-based exercise intervention will be evaluated. The 12-week exercise program will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a partner-based setting twice weekly at a dedicated cancer and exercise lab.

Interventions

Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises

Sponsors

Nova Scotia Health Authority
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(all): * 18+ years * able to perform discontinuous low intensity physical activity at a minimum * able to provide informed written consent in English. Inclusion Criteria (cancer patients/survivors) \- are along any stage of the cancer continuum (i.e., pre-treatment, receiving active treatment, and up to 5 years post-treatment) Inclusion Criteria (informal caregivers) * must be currently providing physical and/or psychological support to an adult (+18 years) cancer patient/survivor * not be exceeding current Canadian physical activity guidelines (i.e., 150 minutes of moderate-to-vigorous physical activity per week)

Exclusion criteria

(all): \- Patients/survivors and caregivers will be excluded from the study if they have any medical conditions that would contraindicate exercise

Design outcomes

Primary

MeasureTime frameDescription
RecruitmentThrough study completion, about 2 yearsParticipant accrual as defined as the number of eligible participant dyads who consents to participate
Intervention AdherenceThrough study completion, about 2 yearsParticipant program adherence calculated as percentage of exercise sessions completed divided by total number of available exercise sessions over 12-week intervention
Adverse EventsThrough study completion, about 2 yearsAdverse and serious adverse events will be recorded
AttritionThrough study completion, about 2 yearsParticipant attrition calculated as percentage of patients who complete 12-week study divided by number who withdraw from study
Participant SatisfactionPost intervention, about 12-weeks after baselineParticipant satisfaction will be assessed by semi-structured interviews (no min/max)

Secondary

MeasureTime frameDescription
Aerobic FitnessPre to post intervention (12-week change)The 6-minute walk test will be used to assess aerobic capacity
Upper Body StrengthPre to post intervention (12-week change)Grip strength will be measured using a hand-held dynamometer
Muscular EndurancePre to post intervention (12-week change)Lower body muscular endurance will be assessed using the 30-second sit-to-stand
BalancePre to post intervention (12-week change)Balance will be assessed using the one-legged stance
FlexibilityPre to post intervention (12-week change)Flexibility will be assessed using the sit-and-reach and shoulder flexibility
Caregiver BurdenPre to post intervention (12-week change)Assessed by the 22-item Zarit Burden Interview (ZBI). Responses are scored on a 5-point Likert scale ranging from 0 (never) to 4 (nearly always) with the sum of scores ranging from 0 to 88 (higher scores indicate higher burden)
Cancer Patient Quality of LifePre to post intervention (12-week change)Quality of life for cancer patients will be assessed using the Functional Assessment of Cancer Therapy - General survey. The combined 27-item scale provides subscale scores physical (7-items), functional (7-items), emotional (6-items), and social/family (7-items) well-being. The sum of scores on the five domains evaluates a participants' quality of life with higher scores (ranging from 0-108) denoting higher quality of life.
Cancer Patient FatiguePre to post intervention (12-week change)Fatigue will be assessed using the 13-item Functional Assessment of Chronic Illness Therapy - Fatigue survey. Scores range from 0-52 with higher scores indicating better functioning/less fatigue
Self-Reported Physical ActivityPre to post intervention (12-week change)Physical activity will be assessed using the Godin Leisure Time Exercise Questionnaire. Total score ranges from 0 to no maximum.
General Health (EuroQol) 5 Dimension - 5 LevelPre to post intervention (12-week change)Mobility, self-care, usual activities, pain/discomfort, anxiety/depression (EuroQol-5Dimension-5Level; EQ-5D-5L); higher scores indicate higher problems (range 0-1)
Caregiver Quality of LifePre to post intervention (12-week change)Quality of life will be assessed using the Short-Form Health Survey- SF-36. The SF-36 consists of 36 questions that cover 8 health domains/subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). The total scale score ranges from 0 to 100 with higher values representing higher quality of life.
Body Mass Index (BMI)Pre to post intervention (12-week change)Weight (kg) and height (m) will be used to calculate BMI
Body CompositionPre to post intervention (12-week change)Waist and hip circumference
Resting heart ratePre to post intervention (12-week change)Resting heart rate
Resting Blood PressurePre to post intervention (12-week change)Resting systolic and diastolic blood pressure

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026